Collagen peptide impacts cardiovascular markers, study finds

“There are currently no comprehensive reviews to assess the effect of CPS on cardiovascular disease-related markers (eg body mass, fat mass, fat-free mass, LDL, HDL, triglycerides, total cholesterol, blood pressure, and fasting blood sugar), which denotes a gap in knowledge,”​ the authors of the review stated.

To fill this gap and reconcile conflicting findings, a team of health and nutrition experts led by researchers from Kemanshah University of Medical Sciences in Iran conducted a systematic review and meta-analysis of relevant randomized controlled trials up to November 2021.

Study selection

The review yielded 239 screened studies of a total of 453 records generated through a methodological search of Scopus, PubMed and ISI Web of Science databases. The search used the controlled vocabulary of Medical Subject Headings and was complemented by an analysis of reference lists derived from individual studies.

“Ultimately, 12 randomized controlled trials, collectively comprising 11 outcome measures, were selected for the quantitative analysis,”​ the research team confirmed.

These eligible studies from Germany, Korea, Japan, China and India included a total of 748 participants – a collection of healthy and overweight participants, as well as individuals with type 2 diabetes mellitus, mild hypertension, osteoarthritis and age-related sarcopenia. The dose of CPS varied from 900 mg/d to 15 g/d, while the duration of the clinical trials ranged from six to 12 weeks.

Using a validated risk of bias assessment, the review determined 10 of the 12 studies to be of high quality and found no signs of publication bias.


Leave a Comment